Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Life Sciences Tools & Services
NASDAQ | Common Stock
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company.
The company operates through two segments, Clinical Solutions and Commercial Solutions.
The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development.
This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs.
The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services.
Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries.
It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform.
The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018.
Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
As of September 28, 2023, Syneos Health, Inc. was taken private.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 9, 23 | 0.57 Decreased by -54.40% | 0.79 Decreased by -27.85% |
| May 10, 23 | 0.75 Decreased by -25.74% | 0.66 Increased by +13.64% |
| Feb 16, 23 | 1.23 Decreased by -16.89% | 1.20 Increased by +2.50% |
| Nov 4, 22 | 1.23 Increased by +0.82% | 1.32 Decreased by -6.82% |
| Aug 2, 22 | 1.25 Increased by +28.87% | 1.20 Increased by +4.17% |
| Apr 29, 22 | 1.01 Increased by +27.85% | 0.95 Increased by +6.32% |
| Feb 17, 22 | 1.48 Increased by +33.33% | 1.43 Increased by +3.50% |
| Nov 3, 21 | 1.22 Increased by +17.31% | 1.17 Increased by +4.27% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 1.37 B Increased by +0.39% | 793.00 K Decreased by -98.98% | Increased by +0.06% Decreased by -98.98% |
| Mar 31, 23 | 1.36 B Increased by +1.54% | -72.15 M Decreased by -256.25% | Decreased by -5.32% Decreased by -253.88% |
| Dec 31, 22 | 1.36 B Decreased by -0.98% | 55.53 M Decreased by -26.90% | Increased by +4.08% Decreased by -26.17% |
| Sep 30, 22 | 1.34 B Decreased by -0.89% | 87.05 M Increased by +11.25% | Increased by +6.51% Increased by +12.25% |
| Jun 30, 22 | 1.36 B Increased by +6.09% | 77.74 M Increased by +85.52% | Increased by +5.71% Increased by +74.87% |
| Mar 31, 22 | 1.34 B Increased by +10.55% | 46.18 M Increased by +19.24% | Increased by +3.46% Increased by +7.87% |
| Dec 31, 21 | 1.37 B Increased by +20.47% | 75.96 M Decreased by -17.33% | Increased by +5.53% Decreased by -31.38% |
| Sep 30, 21 | 1.35 B Increased by +22.68% | 78.24 M Increased by +23.38% | Increased by +5.80% Increased by +0.57% |